Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board

SAN DIEGO, CA - (NewMediaWire) - April 26, 2022 - Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated conditions that inducesepsis and other life-threatening disorders, today announced the appointment of Donald J. Hillebrand,M.D. to its Scientific Advisory Board. 

Dr. Hillebrand is the Associate Medical Director of Liver Transplantation at Saint Luke's Hospital of Kansas City and Associate Professor of Medicine at the University of Missouri Kansas City (UMKC).  He is a recognized leader in the field of Hepatology and Liver Transplantation. In addition to his academic and clinical contributions, Dr. Hillebrand has served as a Principal Investigator in clinical studies of extracorporeal technologies to treat patients suffering from severe liver disorders. Dr. Hillebrand has authored more that 20 Papers Published or In Press/Preparation and 7 books and/or book chapters. He is currently on the Editorial Board, ASAIO Journal, Section Editor ASATO Journal-Liver Transplantation, Website Editor ASAIO Artificial Liver Section and Reviewer, European Journal of Gastroenterology & Hepatology. Dr. Hillebrand graduated with distinction in Microbiology from Iowa State University.  He did his residency in Internal Medicine at Iowa State University Hospitals and Clinics and fellowships in Gastroenterology/Hepatology and Liver Transplantation at Iowa State University Hospitals and Clinics.

About Sigyn Therapeutics™

Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide. Sigyn Therapy™ is a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream. 

Beyond establishing a novel strategy to combat sepsis, candidate treatment indications for Sigyn Therapy include, but are not limited to; emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases. 

To learn more, visit www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties.  Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Stephen Kilmer

Sigyn Therapeutics, Inc.

Investor Relations

(646) 274-3580

stephen@sigyntherapeutics.com

Media Contacts:

Russo Partners, LLC

David Schull

(212) 845-4271

David.Schull@russopartnersllc.com 

Nic Johnson

(212) 845-4242